secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-268102
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics Q3 2025 net loss $21M; divesiran Phase 2 fully enrolled with topline data in 3Q 2026
--------------------------------------------------------------------------------

- Cash and investments $102.2M as of Sept 30, 2025, providing runway into 2028.
- Net loss $21.0M for Q3 2025 vs $35.5M in Q3 2024, primarily due to lower foreign currency loss.
- SANRECO Phase 2 study of divesiran in polycythemia vera fully enrolled (48 patients); topline results expected Q3 2026.
- R&D expenses $20.5M (vs $20.2M YoY); G&A expenses $5.8M (vs $7.7M YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525268102/0001193125-25-268102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525268102/sln-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-268102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer